246 related articles for article (PubMed ID: 30958398)
61. Androgen deprivation therapy for prostate cancer.
Singer EA; Golijanin DJ; Miyamoto H; Messing EM
Expert Opin Pharmacother; 2008 Feb; 9(2):211-28. PubMed ID: 18201145
[TBL] [Abstract][Full Text] [Related]
62. The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy.
Xie T; Song XL; Wang C; Yu YZ; Wang JQ; Chen ZS; Zhao SC
Drug Discov Today; 2021 May; 26(5):1293-1301. PubMed ID: 33561465
[TBL] [Abstract][Full Text] [Related]
63. Androgens and antiandrogens.
Schneider HP
Ann N Y Acad Sci; 2003 Nov; 997():292-306. PubMed ID: 14644837
[TBL] [Abstract][Full Text] [Related]
64. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
65. Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists.
Clyne M
Nat Rev Urol; 2013 Dec; 10(12):679. PubMed ID: 24247426
[No Abstract] [Full Text] [Related]
66. Androgen Deprivation Therapy, Perseverance, and Greek Mythology.
Tree A
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):304-305. PubMed ID: 34998533
[No Abstract] [Full Text] [Related]
67. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
Ryan CJ; Halabi S; Ou SS; Vogelzang NJ; Kantoff P; Small EJ
Clin Cancer Res; 2007 Apr; 13(7):2030-7. PubMed ID: 17404083
[TBL] [Abstract][Full Text] [Related]
68. Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE.
Gong J; Posadas EM
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35877083
[No Abstract] [Full Text] [Related]
69. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
70. The biological and clinical advances of androgen receptor function in age-related diseases and cancer [Review].
Takayama KI
Endocr J; 2017 Oct; 64(10):933-946. PubMed ID: 28824023
[TBL] [Abstract][Full Text] [Related]
71. Testosterone and prostate cancer: what are the risks for middle-aged men?
Morgentaler A
Urol Clin North Am; 2011 May; 38(2):119-24. PubMed ID: 21621078
[TBL] [Abstract][Full Text] [Related]
72. Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.
Walsh PC; Siiteri PK
J Urol; 1975 Aug; 114(2):254-6. PubMed ID: 125803
[TBL] [Abstract][Full Text] [Related]
73. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
[TBL] [Abstract][Full Text] [Related]
74. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
[TBL] [Abstract][Full Text] [Related]
75. Effect of estradiol on cognition in men undergoing androgen deprivation therapy: A randomized placebo-controlled trial.
Russell N; Allebone J; Dandash O; Hoermann R; Cheung AS; Zajac JD; Handelsman DJ; Kanaan RA; Grossmann M
Clin Endocrinol (Oxf); 2022 Nov; 97(5):622-633. PubMed ID: 35150156
[TBL] [Abstract][Full Text] [Related]
76. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
Meza J; Weaver K; Martin S
Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
[No Abstract] [Full Text] [Related]
77. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
78. Is it andropause? Recognizing androgen deficiency in aging men.
Tan RS; Pu SJ
Postgrad Med; 2004 Jan; 115(1):62-6. PubMed ID: 14755879
[TBL] [Abstract][Full Text] [Related]
79. Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer.
Van Poppel H; Werbrouck PW; Baert L
Acta Urol Belg; 1990; 58(4):89-95. PubMed ID: 2093302
[TBL] [Abstract][Full Text] [Related]
80. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.
Zang T; Taplin ME; Tamae D; Xie W; Mesaros C; Zhang Z; Bubley G; Montgomery B; Balk SP; Mostaghel EA; Blair IA; Penning TM
Endocr Relat Cancer; 2017 Aug; 24(8):393-404. PubMed ID: 28663228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
